47.71
0.44%
0.21
시간 외 거래:
47.71
전일 마감가:
$47.50
열려 있는:
$46.92
하루 거래량:
2.41M
Relative Volume:
1.16
시가총액:
$119.62B
수익:
$53.04B
순이익/손실:
$4.93B
주가수익비율:
15.03
EPS:
3.1735
순현금흐름:
$9.91B
1주 성능:
+1.94%
1개월 성능:
-0.15%
6개월 성능:
+1.84%
1년 성능:
-1.04%
사노피 ADR Stock (SNY) Company Profile
SNY을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
47.71 | 119.62B | 53.04B | 4.93B | 9.91B | 1.9736 |
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
사노피 ADR Stock (SNY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-07-26 | 재확인 | Argus | Buy |
2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
2024-01-16 | 재개 | UBS | Buy |
2023-12-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2023-10-30 | 다운그레이드 | Stifel | Buy → Hold |
2023-09-06 | 업그레이드 | Berenberg | Hold → Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-04-28 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2023-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
2022-12-13 | 재개 | Morgan Stanley | Overweight |
2022-08-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
2022-08-09 | 다운그레이드 | UBS | Buy → Neutral |
2022-05-23 | 개시 | SVB Leerink | Outperform |
2021-09-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2021-01-15 | 개시 | Deutsche Bank | Sell |
2020-09-29 | 개시 | Berenberg | Hold |
2020-03-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
2020-03-11 | 업그레이드 | Goldman | Neutral → Buy |
2020-02-11 | 개시 | SVB Leerink | Mkt Perform |
2020-01-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
2019-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2019-09-03 | 개시 | Bernstein | Outperform |
2019-08-14 | 업그레이드 | UBS | Neutral → Buy |
2018-12-11 | 업그레이드 | Jefferies | Hold → Buy |
2018-11-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
2018-10-09 | 개시 | Guggenheim | Neutral |
2018-09-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2018-08-10 | 업그레이드 | Citigroup | Neutral → Buy |
2018-03-23 | 업그레이드 | Liberum | Hold → Buy |
2018-01-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
2017-12-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2017-12-01 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
2017-11-15 | 업그레이드 | Barclays | Underweight → Equal Weight |
2017-08-30 | 업그레이드 | HSBC Securities | Reduce → Hold |
모두보기
사노피 ADR 주식(SNY)의 최신 뉴스
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Communiqué de presse - GlobeNewswire Inc.
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug - Investor's Business Daily
What Did We Find About Insider Trading At Sanofi ADR (NASDAQ: SNY)? - Stocks Register
Weekly Upgrades and Downgrades - InvestorPlace
Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - MSN
Top-3 International Stocks Beating Their U.S. Peers for Dividend Earnings - TheStreet
Novo Nordisk and AstraZeneca top 2025 drug picks for US investment bankread why - Proactive Investors USA
Why Sanofi (SNY) Is One of the Best ADR Stocks to Invest in? - Insider Monkey
12 Best ADR Stocks To Invest In According to Analysts - Insider Monkey
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
How Robert F. Kennedy Jr. Will Bring Major Uncertainties to U.S. Healthcare - Barron's
Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
Here’s Why Mastercard Incorporated (NYSE: MA) Is An Attractive Investment Right Now - Stocks Register
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo Finance
16 New 4-Star Stocks - Morningstar
Biggest stock movers Monday: DJT, crypto stocks, and more - MSN
사노피 ADR (SNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):